Frankfurt - Delayed Quote EUR
Ascelia Pharma AB (7ZA.F)
0.2075
-0.0560
(-21.25%)
At close: April 25 at 8:06:40 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Cost of Revenue
--
--
--
3,892
8,723
Operating Expense
67,765
67,765
110,914
147,670
137,897
Operating Income
-67,765
-67,765
-110,914
-147,670
-137,897
Net Non Operating Interest Income Expense
-12,358
-12,358
1,307
587
-67
Pretax Income
-80,124
-80,124
-109,607
-133,155
-129,523
Tax Provision
-94
-94
-319
-1,933
-3,620
Net Income Common Stockholders
-80,029
-80,029
-109,288
-131,223
-125,903
Diluted NI Available to Com Stockholders
-80,029
-80,029
-109,288
-131,223
-125,903
Basic EPS
-1.48
--
-3.24
-2.61
-2.64
Diluted EPS
-1.48
--
-3.24
-2.61
-2.64
Basic Average Shares
54,001.1870
--
33,719.7790
50,302.0350
47,643.1490
Diluted Average Shares
54,001.1870
--
33,719.7790
50,302.0350
47,643.1490
Total Operating Income as Reported
-67,766
-67,766
-110,914
-147,007
-137,948
Total Expenses
67,765
67,765
110,914
147,670
137,897
Net Income from Continuing & Discontinued Operation
-80,029
-80,029
-109,288
-131,223
-125,903
Normalized Income
-80,029
-80,029
-109,288
-131,223
-125,903
Interest Income
1,584
1,584
3,725
635
10
Interest Expense
13,942
13,942
2,418
48
77
Net Interest Income
-12,358
-12,358
1,307
587
-67
EBIT
-66,182
-66,182
-107,189
-133,107
-129,446
EBITDA
-66,182
-66,182
-107,189
-133,107
-129,446
Reconciled Cost of Revenue
--
--
--
3,892
8,723
Net Income from Continuing Operation Net Minority Interest
-80,029
-80,029
-109,288
-131,223
-125,903
Normalized EBITDA
-66,182
-66,182
-107,189
-133,107
-129,446
Tax Rate for Calcs
0
0
0
0
0
12/31/2021 - 12/11/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade